A common blood pressure drug may help a major class of cancer therapies work far better than expected. A widely prescribed ...

The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

For cancers that harbor gene mutations that weaken DNA repair, poly-ADP ribose polymerase (PARP) is like a crutch. It ensures that these cancers can keep DNA repair going well to survive. But what if ...

A newly discovered molecule disrupts cancer cells’ ability to repair DNA by triggering the breakdown of key proteins. Cancer ...

Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their ...

A new study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

The PARP inhibitor clinical trial analysis report delivers important insights into ongoing research on 30+ PARP inhibitors in the pipeline, clinical strategies, upcoming therapeutics, and commercial ...

Researchers from Tokyo Metropolitan University have identified key factors in the mechanism behind DNA repair in our bodies. For the first time, they showed that the "proofreading" portion of the DNA ...

PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers. Niraparib approved for all-comers whose ...